ArticleFrontiers in pharmacology2026

Onatasertib re-sensitizes refractory nasopharyngeal carcinoma to immunotherapy: a Case Report.

Peipei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.